

Jaya Chakravarty

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/2315295/jaya-chakravarty-publications-by-year.pdf>

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

50
papers

2,158
citations

21
h-index

46
g-index

50
ext. papers

2,487
ext. citations

6.1
avg. IF

5.3
L-index

#	Paper	IF	Citations
50	Geographical Variability in Paromomycin Pharmacokinetics Does Not Explain Efficacy Differences between Eastern African and Indian Visceral Leishmaniasis Patients. <i>Clinical Pharmacokinetics</i> , 2021 , 60, 1463-1473	6.2	3
49	Anti-Interleukin-10 Unleashes Transcriptional Response to Leishmanial Antigens in Visceral Leishmaniasis Patients. <i>Journal of Infectious Diseases</i> , 2021 , 223, 517-521	7	2
48	Xenodiagnosis to evaluate the infectiousness of humans to sandflies in an area endemic for visceral leishmaniasis in Bihar, India: a transmission-dynamics study. <i>Lancet Microbe, The</i> , 2021 , 2, e23-e31	22.2	19
47	Type I Interferons Suppress Anti-parasitic Immunity and Can Be Targeted to Improve Treatment of Visceral Leishmaniasis. <i>Cell Reports</i> , 2020 , 30, 2512-2525.e9	10.6	21
46	Male predominance in reported Visceral Leishmaniasis cases: Nature or nurture? A comparison of population-based with health facility-reported data. <i>PLoS Neglected Tropical Diseases</i> , 2020 , 14, e0007995	4.8	12
45	Factors affecting disclosure of HIV-positive serostatus among people living with HIV/AIDS attending an antiretroviral therapy center of Eastern India. <i>Indian Journal of Public Health</i> , 2020 , 64, 4-10	1.8	1
44	An Unusual Presentation of Post kala-azar Dermal Leishmaniasis. <i>Indian Dermatology Online Journal</i> , 2020 , 11, 269-271	0.9	
43	The utility of banana peel extract agar in the presumptive identification of <i>Cryptococcus neoformans</i> . <i>Journal of Microbiological Methods</i> , 2020 , 177, 106046	2.8	1
42	Clinical and Biochemical Profile in Patients with Rheumatoid Arthritis with Special Reference to Insulin Resistance. <i>Journal of the Association of Physicians of India, The</i> , 2020 , 68, 71	0.4	
41	Meta-taxonomic analysis of prokaryotic and eukaryotic gut flora in stool samples from visceral leishmaniasis cases and endemic controls in Bihar State India. <i>PLoS Neglected Tropical Diseases</i> , 2019 , 13, e0007444	4.8	16
40	Current and emerging medications for the treatment of leishmaniasis. <i>Expert Opinion on Pharmacotherapy</i> , 2019 , 20, 1251-1265	4	63
39	Determinants for progression from asymptomatic infection to symptomatic visceral leishmaniasis: A cohort study. <i>PLoS Neglected Tropical Diseases</i> , 2019 , 13, e0007216	4.8	28
38	Interleukin 2 is an Upstream Regulator of CD4+ T Cells From Visceral Leishmaniasis Patients With Therapeutic Potential. <i>Journal of Infectious Diseases</i> , 2019 , 220, 163-173	7	5
37	Transcriptional blood signatures for active and amphotericin B treated visceral leishmaniasis in India. <i>PLoS Neglected Tropical Diseases</i> , 2019 , 13, e0007673	4.8	11
36	Human Papillomavirus Genome based Detection and Typing: A Holistic Molecular Approach. <i>Current Molecular Medicine</i> , 2019 , 19, 237-246	2.5	6
35	Effectiveness of Single-Dose Liposomal Amphotericin B in Visceral Leishmaniasis in Bihar. <i>American Journal of Tropical Medicine and Hygiene</i> , 2019 , 101, 795-798	3.2	5
34	Leishmaniasis: treatment, drug resistance and emerging therapies. <i>Expert Opinion on Orphan Drugs</i> , 2019 , 7, 1-10	1.1	21

33	Epitope-Binding Characteristics for Risk versus Protective DRB1 Alleles for Visceral Leishmaniasis. <i>Journal of Immunology</i> , 2018 , 200, 2727-2737	5.3	9
32	Human papillomavirus infection & anal cytological abnormalities in HIV-positive men in eastern India. <i>BMC Infectious Diseases</i> , 2018 , 18, 692	4	2
31	Visceral leishmaniasis elimination targets in India, strategies for preventing resurgence. <i>Expert Review of Anti-Infective Therapy</i> , 2018 , 16, 805-812	5.5	30
30	Uttar Pradesh Association of Physicians of India Position Statement: Tobacco Use and Metabolic Syndrome. <i>Journal of the Association of Physicians of India, The</i> , 2017 , 65, 66-72	0.4	1
29	Clinical Abacavir Hypersensitivity Reaction among Children in India. <i>Indian Journal of Pediatrics</i> , 2016 , 83, 855-8	3	5
28	Current challenges in treatment options for visceral leishmaniasis in India: a public health perspective. <i>Infectious Diseases of Poverty</i> , 2016 , 5, 19	10.4	100
27	Suppression of host PTEN gene expression for Leishmania donovani survival in Indian visceral leishmaniasis. <i>Microbes and Infection</i> , 2016 , 18, 369-72	9.3	2
26	Why do Patients in Pre-Anti Retroviral Therapy (ART) Care Default: A Cross-Sectional Study. <i>Indian Journal of Community Medicine</i> , 2016 , 41, 241-4	0.8	6
25	Prevalence of human papillomavirus infection & cervical abnormalities in HIV-positive women in eastern India. <i>Indian Journal of Medical Research</i> , 2016 , 143, 79-86	2.9	18
24	Novel Antigen Detection Assay to Monitor Therapeutic Efficacy of Visceral Leishmaniasis. <i>American Journal of Tropical Medicine and Hygiene</i> , 2016 , 95, 800-802	3.2	8
23	Single-dose indigenous liposomal amphotericin B in the treatment of Indian visceral leishmaniasis: a phase 2 study. <i>American Journal of Tropical Medicine and Hygiene</i> , 2015 , 92, 513-7	3.2	34
22	Investigational drugs for visceral leishmaniasis. <i>Expert Opinion on Investigational Drugs</i> , 2015 , 24, 43-59	5.9	38
21	An update on pharmacotherapy for leishmaniasis. <i>Expert Opinion on Pharmacotherapy</i> , 2015 , 16, 237-52	4	171
20	Outcome of patients on second line antiretroviral therapy under programmatic condition in India. <i>BMC Infectious Diseases</i> , 2015 , 15, 517	4	23
19	Efficacy and safety of miltefosine in treatment of post-kala-azar dermal leishmaniasis. <i>Scientific World Journal, The</i> , 2015 , 2015, 414378	2.2	27
18	Association of interleukin-18 gene polymorphism with susceptibility to visceral leishmaniasis in endemic area of Bihar, an Indian population. <i>Scientific World Journal, The</i> , 2014 , 2014, 852104	2.2	5
17	Quantitative PCR in epidemiology for early detection of visceral leishmaniasis cases in India. <i>PLoS Neglected Tropical Diseases</i> , 2014 , 8, e3366	4.8	33
16	Efficacy and Safety of Paromomycin in Treatment of Post-Kala-Azar Dermal Leishmaniasis. <i>ISRN Parasitology</i> , 2014 , 2014, 548010		8

15	Study the drug adherence and possible factor influencing drug adherence in HIV/AIDS patients in north eastern part of India. <i>Journal of Education and Health Promotion</i> , 2014 , 3, 31	1.4	3
14	Determinants of survival in adult HIV patients on antiretroviral therapy in Eastern Uttar Pradesh: a prospective study. <i>Indian Journal of Medical Research</i> , 2014 , 140, 491-500	2.9	14
13	Leishmaniasis: an update of current pharmacotherapy. <i>Expert Opinion on Pharmacotherapy</i> , 2013 , 14, 53-63	4	183
12	Oral miltefosine for Indian post-kala-azar dermal leishmaniasis: a randomised trial. <i>Tropical Medicine and International Health</i> , 2013 , 18, 96-100	2.3	37
11	Cloning, Expression and Purification of Specific Antigen for Serodiagnosis of Visceral Leishmaniasis. <i>Journal of Molecular Biomarkers & Diagnosis</i> , 2013 , 4, 1000141	2	3
10	Efficacy of miltefosine in the treatment of visceral leishmaniasis in India after a decade of use. <i>Clinical Infectious Diseases</i> , 2012 , 55, 543-50	11.6	198
9	Recent advances in the diagnosis and treatment of kala-azar. <i>The National Medical Journal of India</i> , 2012 , 25, 85-9	0.4	21
8	A clinical trial to evaluate the safety and immunogenicity of the LEISH-F1+MPL-SE vaccine for use in the prevention of visceral leishmaniasis. <i>Vaccine</i> , 2011 , 29, 3531-7	4.1	111
7	Evaluation of rk39 immunochromatographic test with urine for diagnosis of visceral leishmaniasis. <i>Transactions of the Royal Society of Tropical Medicine and Hygiene</i> , 2011 , 105, 537-9	2	10
6	Comparison of short-course multidrug treatment with standard therapy for visceral leishmaniasis in India: an open-label, non-inferiority, randomised controlled trial. <i>Lancet, The</i> , 2011 , 377, 477-86	4.0	245
5	Ambisome plus miltefosine for Indian patients with kala-azar. <i>Transactions of the Royal Society of Tropical Medicine and Hygiene</i> , 2011 , 105, 115-7	2	26
4	Drug resistance in leishmaniasis. <i>Journal of Global Infectious Diseases</i> , 2010 , 2, 167-76	2.8	170
3	Single-dose liposomal amphotericin B for visceral leishmaniasis in India. <i>New England Journal of Medicine</i> , 2010 , 362, 504-12	59.2	299
2	Short-course paromomycin treatment of visceral leishmaniasis in India: 14-day vs 21-day treatment. <i>Clinical Infectious Diseases</i> , 2009 , 49, 914-8	11.6	38
1	Paromomycin in the treatment of leishmaniasis. <i>Expert Opinion on Investigational Drugs</i> , 2008 , 17, 787-94	5.9	66